

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 13, 2022

Century Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

001-40498
(Commission File Number)

84-2040295
(I.R.S. Employer
Identification No.)

3675 Market Street
Philadelphia, Pennsylvania
(Address of principal executive offices)

19104
(Zip Code)

Registrant's telephone number, including area code: **(267) 817-5790**

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| <u>Title of Each Class</u> | <u>Trading Symbol</u> | <u>Name of Exchange on Which Registered</u> |
|--|-----------------------|---|
| Common Stock, par value \$0.0001 per share | IPSC | Nasdaq Global Select Market |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 **Other Events**

On April 13, 2022, Century Therapeutics, Inc. (the "Company") updated information reflected in a slide presentation, which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

Item 9.01 **Financial Statements and Exhibits**

(d) Exhibits

| Exhibit No. | Document |
|-----------------------------|--|
| <u>99.1</u> | <u>Investor Presentation of Century Therapeutics, Inc., dated April 13, 2022</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CENTURY THERAPEUTICS, INC.

By: /s/ Osvaldo Flores, Ph.D.
Name: Osvaldo Flores, Ph.D.
Title: President and Chief Executive Officer

Date: April 13, 2022



21ST ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

April 13, 2022




FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements assumed future results of operations, business strategies, research and development plans, regulatory activities, market opportunity, competitive position and potential growth forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements such as "may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements on current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some are outside our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our ability to maintain and successfully enforce adequate intellectual property protection on certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and final regulatory approval of our product candidates; the impact of the COVID-19 pandemic on our business and operations, supply chain and labor force; the performance of third parties with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the "Risk Factors" section of our most recent filings with the Securities and Exchange Commission at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may or may not occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risks may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not intend to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.







Future Vision



PRECISION CRISPR MAD7 GENE EDITING OF iPSC CELLS UNLOCKS TRANSFORMATIONAL POTENTIAL



ALLO-EVASION™ 1.0 DESIGNED TO OVERCOME THREE MAJOR PATHWAYS OF HOST VS GRAFT REJECTION




Core edits

- 1 Deletion of $\beta 2M$, a protein required for HLA-I on the cell surface prevents recognition by CD8 T cells
- 2 Knock out of CIITA eliminates HLA-II to escape elimination by CD4 T cells
- 3 Knock-in of HLA-E prevents killing by NK cells

CENTURY'S PROTEIN SCIENCES ENABLES ALL ASPECTS OF PROTEIN ENGINEERING OF OUR PRODUCT CANDIDATES

CAR Structure



CAR Engineering

- **Enable fit-for-purpose CAR assembly**
 - Multiple CAR formats for single- and multi-specific CARs
- **CAR Binder Discovery**
 - Century Therapeutics' proprietary VHH library
 - Partnerships with Distributed Bio and LakePharma
- **Signaling Domains**
 - Signaling domains specifically optimized for iNK and iT cells

Transgene Engineering

- Allo-Evasion molecules
- Safety switch
- Cytokines
- Chimeric proteins

CRISPR-MAD7 Protein Engineering

- Protein optimization, production, and characterization

STATE-OF-THE ART MANUFACTURING

DESIGNED TO POSITION CENTURY
IN iPSC-BASED CELL THERAPY FC



Century's multi-suite facility
Branchburg, NJ

- cGMP manufacturing facility expected to be operational in 2022
 - 53,000 ft² facility
- Capable of production of NK and T cells, as well as other cell types

Advantages of investing in manufacturing expertise

- Fully integrated analytical and process control manufacturing
- More effectively implement process and scale
- Potentially accelerate clinical development to commercial product
- Potential to achieve economies of scale




CELL ENGINEERING ENABLES RAPID PRODUCT ITERATION


Century's Platform allows for potent transformative product evolution

| Proposed Feature | CNTY-101 iNK 1.0 | CNTY-103 iNK 2.0 | iNK 3.0 Illustrative |
|---------------------|---------------------|---------------------|-------------------------|
| Cytokine support | Soluble IL-15 | mbIL-15 | mbIL-15 |
| Innate Activity | + | ++ (NKG2A KO) | ++ (NKG2A KO) |
| Undisclosed | | | ✓ |
| PET tracer | | | ✓ |
| Allo-Evasion | | | |
| HLA-I KO | ✓ | ✓ | ✓ |
| HLA-II KO | ✓ | ✓ | ✓ |
| HLA-E KI | ✓ | ✓ | ✓ |
| Undisclosed | | | ✓ |
| # of edits | 6 | 6 | 12 |
| KO | 2 | 3 | 4 |
| Site-specific KI | 4 | 3 | 8 |

Fit for purpose tailored function



CENTURY'S FIRST GENERATION $\gamma\delta$ CAR-iT CELLS MULTIPLE BUILT-IN PATHWAYS FOR TUMOR KILLING




PATHWAYS FOR TUMOR KILLING


1. CAR-mediated killing
2. ADCC (Antibody-Dependent Cellular Cytotoxicity)
3. Innate-receptor killing (NKG2D, MICA/MICB)

$\gamma\delta$ CAR-iT CELLS KILL LYMPHOMA CELLS THROUGH MULTIPLE ROUNDS OF KILLING WITHOUT REACHING EXHAUSTION

Serial Killing Assay Setup



Serial Killing of CD19⁺ Lymphoma Cells by $\gamma\delta$ CAR-iT



CENTURY'S EMERGING FRANCHISES



B cell malignancies

- **CNTY-101:** Lead product candidate, CD19 targeted CAR-iNK
- **CNTY-102:** First $\gamma\delta$ iT candidate, multi-specific (CD19 + CD79b) CAR-iT

Potentially first product candidate in clinic with edits designed to overcome inhibitory pathways of rejection

CNTY-102 provides optional edits for additional subtypes / use in combination



Glioblastoma

- **CNTY-103:** Multi-specific (CD133+ EGFR) CAR iNK for recurrent GBM
- **Follow-on candidate**

Multi-tumor antigen targeting to overcome heterogeneity in GBM tumors

Exploring additional tumor antigens and TME modulation features



Solid tumors

- **Future candidate** expected to be announced 4Q 2022


Leverage $\gamma\delta$ iT platform to address challenging solid tumor targets



CNTY-101: NEXT GENERATION CD19 TARGETED PRODUCT

HIGHLY DIFFERENTIATED PROFILE

Allo-Evasion™ edits



CNTY-101


First cell product candidate with 6 gene edits introduced with CRISPR-HDR



ELIPSE-1: PHASE 1 STUDY DESIGN


- Explore 1 to 2 cycles up to 6 doses with conditioning
- Effect of Allo-Evasion on iNKT persistence multiple doses
 - IND expected mid-2022 to advance into Phase 1 clinical trial

ELIPSE-1 Schedule B



* Subject to FDA approval

CNTY-103: FIRST PROGRAM IN CNS MALIGNANCIES




- **Targeting EGFR+ GBMs:** Provides better coverage intended to ensure maximum tumor clearance
- **Targeting CD133+ GBMs:** Clears functionally relevant treatment-resistant tumor cells


UNIQUELY POSITIONED TO ADDRESS CHALLENGES OF GBM

| Challenge | Century's |
|---------------|---|
| Trafficking | Local delivery with |
| Heterogeneity | Targeting EGFR and CD133 (functionally treatment-resistant) |
| Toxicity | Potentially minimized with |
| Persistence | Potential to deliver |

MULTIPLE CAR DESIGNS AND SIGNALING DOMAINS V INVESTIGATED TO DEVELOP THE CD133xEGFR CAR



Comparison Of The Cytotoxic Activity Of Multiple CD133xEGFR Constructs Engineered With Different Signaling Domain



PIPELINE

Product candidate pipeline across cell types and targets in solid and hematologic

| Product | iPSC Platform | Targets | Indications | Expected IND Submission | Discovery | Preclinical | Clinical | C |
|----------|---------------|----------------|------------------------|-------------------------|-----------|-------------|----------|---|
| CNTY-101 | iNK | CD19 | B-Cell Malignancies | Mid 2022 | | | | |
| CNTY-103 | iNK | CD133 + EGFR | Glioblastoma | 2023 | | | | |
| CNTY-102 | iT | CD19 + CD79b | B-Cell Malignancies | 2024 | | | | |
| CNTY-104 | iNK/iT | Multi-specific | Acute Myeloid Leukemia | 2024 | | | | |
| CNTY-106 | iNK/iT | Multi-specific | Multiple Myeloma | 2024 | | | | |

Solid Tumors Hematologic Tumors



CENTURY THERAPEUTICS' UNIQUE INVESTMENT OPPORTUNITY

- Well capitalized with cash runway into 2025
 - Financial strength maintained by operational synergies
- Comprehensive end-to-end allogeneic platform
 - iPSC derived iNK and iT cells, world-class gene editing, protein engineering and manufacturing
- CNTY-101 IND submission on track for mid-2022
 - CD19 targeted cell product designed to avoid 3 pathways of host rejection
- CNTY-103 IND enabling activities to initiate in 2022
 - Century's first solid tumor candidate for GBM
- Experienced partner on board to tackle challenging malignancies
 - Bristol-Myers Squibb brings expertise in oncology and hematology





THANK YOU

